Last reviewed · How we verify
AdreView
AdreView is a radiolabeled imaging agent that binds to norepinephrine transporters in cardiac sympathetic nerve terminals to visualize myocardial innervation.
AdreView is a radiolabeled imaging agent that binds to norepinephrine transporters in cardiac sympathetic nerve terminals to visualize myocardial innervation. Used for Cardiac imaging to assess myocardial sympathetic innervation in heart failure and cardiomyopathy, Risk stratification in patients with heart failure.
At a glance
| Generic name | AdreView |
|---|---|
| Sponsor | Timothy M. Bateman |
| Drug class | Cardiac sympathetic imaging agent |
| Target | Norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
AdreView uses iodine-123 labeled metaiodobenzylguanidine (MIBG), a norepinephrine analog, to image the integrity and function of cardiac sympathetic innervation. The agent is taken up by sympathetic nerve terminals via the norepinephrine transporter and retained in storage vesicles, allowing scintigraphic visualization of regional myocardial sympathetic denervation. This imaging capability helps assess cardiac autonomic dysfunction in various heart conditions.
Approved indications
- Cardiac imaging to assess myocardial sympathetic innervation in heart failure and cardiomyopathy
- Risk stratification in patients with heart failure
Common side effects
- Hypersensitivity reactions
- Radiation exposure
Key clinical trials
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (PHASE3)
- Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) (PHASE2)
- Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors (EARLY_PHASE1)
- International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device (PHASE3)
- 123-I mIBG (AdreView) Heart-to-Mediastinal (H/M) Ratio and SPECT Imaging on a Small Field of View-High Efficiency Cardiac SPECT System (PHASE4)
- Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) Imaging (PHASE1)
- 123I-mIBG SPECT Imaging (PHASE3)
- Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AdreView CI brief — competitive landscape report
- AdreView updates RSS · CI watch RSS
- Timothy M. Bateman portfolio CI